»» Подробно о лекарствах »» F. Hoffmann-La Roche »» Пульмозим
 Здоровый образ жизни с современными технологиями Соглашение об использовании 

Монография
Пульмозим

Содержание

Резюме

Совокупность данных, полученных в краткосрочных и длительных клинических исследованиях, показывает, что Пульмозим переносится хорошо. Помимо значительного и стойкого улучшения функции легких, происходит уменьшение риска обострения инфекций дыхательных путей и улучшение качества жизни. Хроническое назначение Пульмозима в комбинации с обычным лечением муковисцидоза хорошо переносится и эффективно у больных с легкой и умеренной степенью поражения легких при муковисцидозе.

В отношении хронического использования Пульмозима в комбинации со стандартной терапией муковисцидоза у больных с ФЖЕЛ ≥ 40% от должного и в возрасте не моложе 5 лет можно сделать следующие заключения:

Таким образом, постоянное применение Пульмозима показано для лечения муковисцидоза в сочетании со стандартной терапией этого заболевания.

Библиография

  1. Dodge JA, Morison S, Lewis PA et al. Cystic fibrosis in the United Kingdom, 1968–1988: incidence, population and survival. Paediatric and Perinatal Epidemiology 1993; 7: 157–166.
  2. Epidemiologic Registry of Cystic Fibrosis Advisory Board. ERCF annual report 1998. Published 2000.
  3. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathologic study. American Journal of Diseases of Children 1938; 56: 344–399.
  4. Fitz Simmons SC. The changing epidemiology of cystic fibrosis. Journal of Pediatrics 1993; 122: 1–9.
  5. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46: 881–885.
  6. Boat TF. Cystic Fibrosis. In: Textbook of Respiratory Medicine, JF Murray, JA Nadel (eds). Saunders WB, Philadelphia (1988), Vol. 1, pp1126–1152.
  7. Penketh ARL, Wise A, Mearns MB et al. Cystic fibrosis in adolescents and adults. Thorax 1987; 42: 526–532.
  8. Kerem E, Reisman J, Corey M et al. Prediction of mortality in patients with cystic fibrosis. New England Journal of Medicine 1992; 326: 1187–1191.
  9. Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. British Medical Bulletin 1992; 48: 912–930.
  10. Zabner R, Quinn JP. Antimicrobials in cystic fibrosis: emergence of a resistance and implications for treatment. Seminars in Respiratory Infections 1992; 7: 210–217.
  11. Shalit I, Stutman HR, Marks MI et al. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987; 82: 189–195.
  12. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. New England Journal of Medicine 1999; 340: 23–30.
  13. Eggleston PA, Rosenstein BJ, Stackhouse CM, Alexander MF. Airway hyperreactivity in cystic fibrosis. Chest 1988; 94: 360–365.
  14. Wanner A, Rao A. Clinical indications for and effects of bland, mucolytic and antimicrobial aerosols. American Review of Respiratory Diseases 1980; 122: 79–87.
  15. Eigen H, Rosenstein BJ, Fitz Simmons S et al. A multicentre study of alternate-day prednisolone therapy in patients with cystic fibrosis. Journal of Pediatrics 1995; 126: 515–523.
  16. Rommens JM, Iannuzzi MC, Kerem BS et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 1989; 245: 1059–1065.
  17. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: Cloning and characterisation of complementary DNA. Science 1989; 245:1066–1073.
  18. Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983; 301: 421–422.
  19. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiecstasis. Pediatrics 1959; 24: 739–745.
  20. Potter J, Matthews LW, Lemm J, Spector S. The composition of pulmonary secretions from patients with and without cystic fibrosis. American Journal of Diseases of Children 1960; 100: 493–495.
  21. Matthews LW, Spector S, Lemm J, Potter JL. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. American Review of Respiratory Diseases 1963; 88: 199–204.
  22. McCarty M. Purification and properties of deoxyribonuclease isolated from beef pancreas. Journal of General Physiology 1946; 29: 123–139.
  23. Armstrong JB, White JC. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet 1950; 2: 739–742.
  24. Chernick WS, Barbero GJ, Eichel HJ. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics 1961; 27: 589–596.
  25. Elmes PC, White JC. Deoxyribonuclease in the treatment of purulent bronchitis. Thorax 1953; 8: 295–300.
  26. Salomon A, Herchfus JA, Segal MS. Aerosols of pancreatic dornase in bronchopulmonary disease. Annals of Allergy 1954; 12: 71–79.
  27. Spier R, Witebsky E, Paine JR. Aerosolized pancreatic dornase and antibiotics in pulmonary infections. Journal of the American Medical Association 1961; 178: 878–886. Epidemiologic Registry of Cystic Fibrosis Advisory Board. ERCF annual report 1998. Published 2000.
  28. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. Journal of the American Medical Association 1968; 205: 312–313.
  29. Parker RH, Wilcox WD, Dietrich TS. Toxicity of intrathecally administered pancreatic dornase. Journal of the American Medical Association 1965; 192: 177–179.
  30. Raskin P. Bronchospasm after inhalation of pancreatic dornase. American Review of Respiratory Diseases 1968; 98: 697–698.
  31. Lieberman J. Enzymatic dissolution of pulmonary secretions. American Journal of Diseases of Children 1962; 104: 342–348.
  32. Funakoshi A, Tsubota Y, Wakasugi H et al. Purification and properties of human pancreatic deoxyribonuclease I. Journal of Biochemistry 1977; 82: 1771–1777.
  33. Murai K, Yamanaka M, Akagi K et al. Purification and properties of deoxyribonuclease from human urine. Biochimica et Biophysica Acta. 1978; 517: 186–194.
  34. Love JD, Hewitt RR. The relationship between human serum and human pancreatic DNase I. Journal of Biological Chemistry 1979; 254: 12588–12594.
  35. Ito K, Minamiura N, Yamamoto T. Human urine DNase I: Immunological identity with human pancreatic DNase I and enzymic and proteochemical properties of the enzyme. Journal of Biochemistry 1984; 95: 1399–1406.
  36. Liao T-H, Salnikow J, Moore S, Stein WH. Bovine pancreatic deoxyribonuclease A. Isolation of cyanogen bromide peptides: complete covalent structure of the polypeptide chain. Journal of Biological Chemistry 1973; 248: 1489–1495.
  37. Suck D, Oefner C, Kabsch C. Three-dimensional structure of bovine pancreatic Dnase I at 2.5Б resolution. EMBO Journal 1984; 3: 2423–2430.
  38. Oefner C, Suck D. Crystallographic refinement and structure of Dnase I at 2Б resolution. Journal of Molecular Biology 1986; 192: 605–632.
  39. Shak S, Capon DJ, Hellmiss R et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Science – USA 1990; 87: 9188–9192.
  40. Green JD. Pharmacological-toxicological expert report on recombinant human deoxyribonuclease I (rhDNase; Pulmozyme®). Human and Experimental Toxicology 1994; 13 (Suppl 1): S1–S42.
  41. Hubbard RC, McElvaney NG, Birrer P et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. New England Journal of Medicine 1992; 326: 812–815.
  42. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proceedings of the National Academy of Science – USA 1974; 71: 4742–4746.
  43. Pinder JC, Gratzer WB. Investigation of the actin-deoxyribonuclease I interaction using a pyreneconjugated actin derivative. Journal of Biochemistry 1982; 21: 4886–4890.
  44. Sinicropi D, Gibson U, Baker D et al. Assays for determination of serum DNase concentration in normal and cystic fibrosis subjects following administration of aerosolized recombinant human DNase. Pediatric Pulmonology 1991; 6: 300.
  45. Aitken ML, Burke W, McDonald G et al. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase I study. Journal of the American Medical Association 1992; 267: 1947–1951.
  46. Ramsey BW, Astley SJ, Aitken ML et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease 1993; 148: 145–151.
  47. Ranasinha C, Assoufi B, Shak S et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199–202.
  48. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 1994; 331: 637–642.
  49. Data on file, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  50. Fiel SB, Fuchs HJ, Johnson C et al. Comparison of three jet nebuliser aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. Chest 1995; 108: 153–156.
  51. Hodson ME. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995; 151: S70–S74.
  52. Ramsey BW et al. A summary of the results of the Phase III multicentre clinical trial: Aerosol administration of recombinant human DNase reduces the risk of respiratory tract infections and improves pulmonary function in patients with cystic fibrosis. Paediatric Pulmonology 1993; Suppl 9: 152–153.
  53. Rosenstein BJ, Johnson CAC et al. Long-term follow-up of Phase III rhDNase trial. Pediatric Pulmonology 1994; Suppl 10: 113–114.
  54. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respiratory Medicine 1995; 89: 499–502.
  55. Parsons HG, Beaudry P, Dumas A, Pencharz PB. Energy needs and growth in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1983; 2: 44–49.
  56. Vaisman N, Pencharz PB, Corey M et al. Energy expenditure of patients with cystic fibrosis. Journal of Pediatrics 1987; 111: 496–500.
  57. Shepherd RW, Holt TL, Vasques-Valesquez L et al. Increased energy expenditure in young children with cystic fibrosis. Lancet 1988 Jun II; I (8598) 1300–1303.
  58. Kane RE, Hobbs P. Energy and respiratory metabolism in cystic fibrosis: The influence of carbohydrate content of nutritional supplements. Journal of Pediatric Gastroenterology and Nutrition 1991; 12: 217–223.
  59. Fried MD, Durie PR, Tsui LC et al. The cystic fibrosis gene and resting energy expenditure. Journal of Pediatrics 1991; 119: 913–916.
  60. Amin N, Dozor AJ. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis. Pediatric Pulmonology 1994; 18: 150–154.
  61. Harms HK, Matouk E, Tournier G et al. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. Pediatric Pulmonology 1998; 26: 155–161.
  62. Shah PL, Bush A, Canny GJ et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. European Respiratory Journal 1995; 8: 954–958.
  63. Johnson C. Multicentre, double-blind, placebo-controlled study to evaluate the safety and efficacy of aerosolized rhDNase therapy in patients with cystic fibrosis who have advanced lung disease. Pediatric Pulmonology 1994; (Suppl 10): 115 (Abstract S8.2).
  64. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996; 110: 889–895.
  65. Accurso FJ. Aerosolised dornase alfa in cystic fibrosis patients with clinically mild lung disease. Dornase Alfa Clinical Series 1995; 2: 1–6.
  66. Konstan MW, Hilliard KA, Norvell TM et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. American Journal of Respiratory and Critical Care Medicine 1994; 150: 448–454.
  67. Shah PL, Scott SF, Geddes DM et al. An evaluation of two aerosol delivery systems for rhDNase. European Respiratory Journal 1997; 10: 1261–1266.
  68. Shah PL, Scott SF, Geddes DM et al. A multicentre evaluation of the clinical efficacy of two aerosol delivery systems for rhDNase. Thorax 1995; 50 (Suppl 2): P52.
  69. Wagener JS, Rock MJ, McCubbin MM et al. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Journal of Pediatrics 1998; 133: 486–491.
  70. Geller DE, Eigen H, Fiel SB et al. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatric Pulmonology 1998; 25: 83–87.
  71. Quan JM, Tiddens HAWM, Sy JP et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis and mild lung function abnormalities. Journal of Pediatrics 2001; 139: 813–820.
  72. Wang X, Dockery DW, Wypij D et al. Pulmonary function between 6 and 19 years of age. Pediatric Pulmonology 1993; 15: 75–88.
  73. Knudsen RJ, Lobowitz MD, Holberg CJ et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. American Review of Respiratory Diseases 1983; 127: 725–734.
  74. Liou TG, Adler FR, Fitz Simmons SC et al.Predictive 5-year survivorship model of cystic fibrosis. American Journal of Immunology 2001; 153: 345–352.


o1
»» Подробно о лекарствах »» F. Hoffmann-La Roche »» Пульмозим



Top100